CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience

Abstract excerpt

Mantle cell lymphoma (MCL) makes up 5% to 6% of all non-Hodgkin lymphomas. 1,2The risk of secondary central nervous system (SCNS) involvement in MCL is ~4%, with 0.9% having CNS involvement at diagnosis. 1 The median survival from time of CNS diagnosis was historically <4 months. 1 Limited data have shown that Bruton tyrosine kinase inhibitors can achieve biologically relevant concentrations in CNS and may...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research
• Share to CNS Lymphoma Diagnosis and Treatment
• Share to Lymphoma Diagnosis and Treatment